CoChat
Sign Up
Cited by 119Pharmacogenetics and Drug MetabolismAdrenal Hormones and DisordersAdrenal and Paraganglionic Tumors

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Mitotane has a strong and a durable inducing effect on CYP3A4 activity

van Erp, Nielka P, Guchelaar, Henk-Jan, Ploeger, Bart A, Romijn, Johannes A, Hartigh, Jan den, Gelderblom, Hans·2011·European Journal of Endocrinology
DOI 10.1530/eje-10-0956
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The effects of mitotane on the pharmacokinetics (PK) of co-administered drugs are mostly unknown. The aim of the present study was to describe the effects of mitotane on the PK of the phenotypic probe midazolam and of the tyrosine kinase inhibitor sunitinib. DESIGN: A serendipitous observation was made in two of nine patients who volunteered in a sunitinib pharmacokinetic study. Both patients were diagnosed with adrenocortical carcinoma (ACC) and were exposed to mitotane. The sunitinib PK study was designed to determine the relationship between CYP3A4 activity and sunitinib exposure using 7.5 mg midazolam orally as a phenotypic probe. Patient and methods Serial blood samples for PK analysis of midazolam, 1-hydroxy-midazolam, and sunitinib were collected at steady-state sunitinib PK (between days 14 and 20). To confirm this observation in the mitotane-exposed patients, midazolam PK was evaluated in two additional patients with ACC and mitotane treatment. RESULTS: The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008). Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg×h/l versus 1344 (1079-1609) (mean (95% CI)) μg×h/l). CONCLUSION: Mitotane has a strong and long-lasting inducing effect on CYP3A4 activity, which will result in clinically relevant interactions with multiple drugs since many drugs are metabolized by this enzyme.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-10-0956

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 119

Related

See all

Metadata

Authors
van Erp, N. P., Guchelaar, H.-J., Ploeger, B. A., Romijn, J. A., Hartigh, J. D., & Gelderblom, H.
Affiliations
Leiden University Medical Center (NL)
ORCID
Venue
European Journal of Endocrinology
Publisher
Oxford University Press (OUP)
Published
2011-04
Volume
164
Issue
4
Pages
621-626
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
DOI
10.1530/eje-10-0956
OpenAlex
W2142711036
Cited by
118
References
25
Citations by year
2026: 4 · 2025: 2 · 2024: 6 · 2023: 4 · 2022: 14 · 2021: 7 · 2020: 9 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 6 · 2015: 12 · 2014: 6 · 2013: 11 · 2012: 14
FWCI
11.44
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Keywords
mitotane, CYP3A4 induction, midazolam, sunitinib, drug-drug interactions, adrenocortical carcinoma, pharmacokinetics, midazolam hydroxylation, tyrosine kinase inhibitors
MeSH terms
Sunitinib, Adult, Aged, Antineoplastic Agents, Enzyme Activation, Female, Humans, Indoles, Male, Middle Aged, Mitotane, Pyrroles, Adrenocortical Carcinoma, Cytochrome P-450 CYP3A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review